10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

MAGEC2 Antibody

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP51326

Product Information

Application	WB
Primary Accession	Q9UBF1
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Calculated MW	41163

Additional Information

Gene ID	51438
Other Names	Melanoma-associated antigen C2, Cancer/testis antigen 10, CT10, Hepatocellular carcinoma-associated antigen 587, MAGE-C2 antigen, MAGE-E1 antigen, MAGEC2, HCA587, MAGEE1
Dilution	WB~~1:1000
Format	0.01M PBS, pH 7.2, 0.09% (W/V) Sodium azide, Glycerol 50%
Storage	Store at -20 °C.Stable for 12 months from date of receipt

Protein Information

Name	MAGEC2
Synonyms	HCA587, MAGEE1
Function	Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.
Cellular Location	Cytoplasm. Nucleus. Note=Nuclear in germ cells. Cytoplasmic in well-differentiated hepatocellular carcinoma, nuclear in moderately- and poorly-differentiated hepatocellular carcinoma
Tissue Location	Not expressed in normal tissues, except in germ cells in the seminiferous tubules and in Purkinje cells of the cerebellum. Expressed in various tumors, including melanoma, lymphoma, as well as pancreatic cancer, mammary gland cancer, non-small cell lung cancer and liver cancer. In hepatocellular

carcinoma, there is an inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression.

Background

Proposed to enhance ubiquitin ligase activity of RING- type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.

References

Gure A.O.,et al.Int. J. Cancer 85:726-732(2000).
Lucas S.,et al.Int. J. Cancer 87:55-60(2000).
Wang Y.,et al.J. Immunol. 169:1102-1109(2002).
Ross M.T.,et al.Nature 434:325-337(2005).
Li B.,et al.Lab. Invest. 83:1185-1192(2003).